Reasons for accepting or declining participation in the ASPRE trial : a qualitative study with women at high‐risk of preterm pre‐eclampsia by Nikcevic, Ana V. et al.
This is the peer reviewed version of the following article: Nikcevic, Ana V., Dodd, Zoe, Prior, Jess, 
O'Gorman, Neil, Poon, Liona C. and Nicolaides, Kypros H. (2019) Reasons for accepting or declining 
participation in the ASPRE trial : a qualitative study with women at high‐risk of preterm pre‐eclampsia. 
Prenatal Diagnosis, 39(12), pp. 1127-1135. , which has been published in final form at 
https://doi.org/10.1002/pd.5554. This article may be used for non-commercial purposes in accordance with 
Wiley Terms and Conditions for Use of Self-Archived Versions."

 
This article has been accepted for publication and undergone full peer review but has not been 
through the copyediting, typesetting, pagination and proofreading process which may lead to 
differences between this version and the Version of Record. Please cite this article as doi: 
10.1002/pd.5554 
 
This article is protected by copyright. All rights reserved. 
Nikcevic Ana V. (Orcid ID: 0000-0002-5311-5704) 
 
Reasons for accepting or declining participation in the ASPRE trial: A 




Date of submission: 03/04/2019 
Word count excluding references: 5328 
Date of submission of revision 1: 15/07/2019 
 
Ana V. Nikčević*, PhD 
Kingston University, Kingston-Upon-Thames, UK 
Zoe Dodd, MSc 
Kingston University, Kingston-Upon-Thames, UK 
 
Jess Prior, PhD 
Kingston University, Kingston-Upon-Thames, UK 
 
Neil O’Gorman  
King’s College Hospital, London, UK 
 
Liona C. Poon 
Chinese University of Hong Kong, Hong Kong 
 
Kypros H. Nicolaides 
King’s College Hospital, London, UK 
 
Correspondence should be addressed to: *Ana Nikčević, PhD, Department of Psychology, 
Kingston University, Kingston-Upon-Thames, KT1 2EE, United Kingdom. Tel. +44 (0)20 




This article is protected by copyright. All rights reserved. 
What is already known about this topic? 
 Motives for participation in medicated clinical trials in pregnancy include the 
potential health benefit of the trial participation, satisfaction with the received 
information, safety of the trial procedure and altruism; 
 Less is known about reasons for declining, in particular amongst those at high-risk; 
avoidance of harm and practical barriers appear to play a role. Concerns about the 
placebo and negation of high-risk status have also been suggested as possible reasons. 
 
What does this study add? 
 A deeper understanding of reasons that facilitate, and hinder, women’s participation 
in medicated clinical trials in pregnancy, especially in those identified as high-risk;  
 A proposal to integrate psychological theories in an attempt to understand why 
women, when presented with the same risk status information, chose different 
behavioural pathways (ie taking part or declining participation in a clinical trial) to 
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Abstract 
Objective: To identify factors that affected the decision of pregnant women at high-risk for 
preeclampsia (PE) in accepting or declining participation in a medicated clinical trial 
(ASPRE) for the prevention of preterm-PE. 
Method:  This was a qualitative, cross-sectional study. A purposive sample of 14 participants 
and 13 decliners of the ASPRE trial were interviewed using semi-structured interviews. Data 
were analysed using template analysis. 
Results: For participants, their high-risk status seem to have motivated them to take part in 
the trial. This was enabled by their perception that the trial drug aspirin was commonly used, 
the safety of the procedure, and the belief that they will be in receipt of extra monitoring in 
pregnancy. Decliners expressed discomfort about taking medications in pregnancy, and about 
the presence of the placebo arm; they seemed to be motivated by desire to reduce harm. 
Satisfaction with the information provided by the medical professionals was also influential 
in women’s decision making, and so were the views of their partners and other trusted 
individuals.  
Conclusion: Pregnant women’s motivation to take part or to decline participation in a 
medicated trail can be understood as an attempt to cope with the threat posed by their high-
risk status.  
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Introduction 
Due to concerns over maternal and fetal safety, pregnant women were excluded from clinical 
trials before 19931. Since then, there has been a growing recognition of the importance of 
involving pregnant women in clinical trials in order to develop knowledge regarding the 
safety and effectiveness of medical interventions in this population. Currently, responsible 
inclusion of pregnant women in medicated trials with adequate monitoring is not only 
recommended but also encouraged2.  
Recruitment rates for pregnancy trials are low with only about 30% of eligible women 
choosing to participate3,4. Little is known about factors that influence participation in clinical 
trials during pregnancy and in particular in medicated clinical trials5,6.  The most commonly 
given reasons for participation include potential health benefits to the mother and/or the 
baby7-9, potential for superior care based on trial participation8,9, satisfaction with the 
information received8-12, absence of perceived harm of the research9,11, and altruism9,10. There 
have only been three studies, to date, that have examined pregnant women’s reasons for 
declining participation in medicated trials7,11,12 . Understanding reasons for not taking part is 
of crucial importance as success of a trial depends on satisfactory recruitment. The reasons 
suggested so far include: risk limitation to the pregnancy, presence of the placebo arm, lack 
of satisfaction with the information about the trial and practical barriers7,11,12. In a study 
involving decliners at high-risk (for preterm labour), some women rejected participation 
based on their negation of their high-risk status12. Although it has been suggested that 
recruitment is influenced by the perceived trial relevance13, it is not clear to what extent the 
health risk status of the pregnant women or their perception of their health risk plays a role in 
women’s decision-making.  
Psychological theories14, such as for example the self-regulation theory15suggest that, 
when faced with a new health threat (e.g. an illness or an abnormal screening result), 
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individuals will form their own representations of that threat. Behavioural changes to 
ameliorate the threat will be dependent on the extent to which an individual perceives the risk 
as significant and personal, as well as the extent to which they believe that a change in their 
behaviour could impact the risk status and the outcome,16,17. The relevance of psychological 
theories that consider these processes has not been explored thus far with ‘at-risk’ 
participants and decliners of medicated trials in pregnancy.  
Studies regarding participation in medicated clinical trials, with rare exceptions11, 
have been limited by the significant time lapse, extending to several years, between the actual 
decision-making regarding participation in the trial and the recounting of the experience. 
Such methodological limitations very likely introduced numerous possible biases (e.g. 
memory bias, bias influenced by the outcome of the pregnancy or the effectiveness of the trial 
drug) relating to the recall of the relevant information. Additionally, the majority of studies 
only sampled either those who participated, or only those who declined, offering in such a 
way a limited understanding of the factors influencing participation in medicated trials in 
pregnancy.   
The aim of the current qualitative study was to elucidate the decision-making of 
pregnant women invited to take part in a medicated trial, i.e. the ASPRE trial, which 
examined whether daily use of a low-dose aspirin would reduce the incidence of preterm-
preeclampsia (PE) in high-risk women. High-risk women were identified by the first 
trimester screening combined test and then randomly assigned to either 150 mg aspirin per 
day, or placebo, from 11 to 14 weeks until 36 weeks’ gestation. Out of 2641 women eligible 
for inclusion in the ASPRE trial across the participating centres in six different European 
countries, 33% declined to participate and a further 8.5% withdrew consent after 
randomisation18. Our study examined the views of eligible UK-based women. 
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By understanding reasons for women’s decision to take part or to decline participation 
in the ASPRE trial, our study aims to offer insights that could inform recruitment into future 
medicated perinatal trials. Furthermore, some of the concerns expressed by the decliners 
could potentially be relevant to medical professionals offering therapeutic prophylaxis to 
women at high-risk of preterm PE. The strength of the adopted design was in that this study 
was nested within the ongoing ASPRE trial, and the use of qualitative methodology enabled 
in-depth exploration of women’s explanations of participation and non-participation.  
Methods 
Study Design and Sample 
A qualitative approach was adopted using semi-structured interviews (topic guide is given in 
Table 1) that allowed in depth exploration of the influences on women’s decision of whether 
or not to participate in the trial. The schedule was flexible enough to allow participants to 
introduce new issues of relevance. A purposive sample19 of both participants (n = 14) and 
decliners (n = 13) of the ASPRE trial, all identified to be at high-risk for preterm-PE, were 
recruited from two London hospitals that participated in the ASPRE trial. The mean 
gestational age at time of interview was 21+5 weeks’ gestation for participants (SD = 4.19), 
and 26+3 weeks for decliners (SD = 6.41) 
Procedure 
Pregnant women attending their 11-14 weeks’ ultrasound appointment at two London 
hospitals were offered the opportunity to be screened for preterm-PE risk status. Women who 
took part were identified as either screen negative, i.e. low-risk for developing preterm-PE, or 
screen positive, i.e. high-risk for developing preterm-PE. Study inclusion criteria and 
procedure of the ASPRE trial have been published previously18.  
Women at high-risk of PE who had either accepted or declined participation in the 
ASPRE trial were mailed information about the current study together with a reply form and 
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a pre-paid envelope. They were informed that the research team was carrying out an 
independent evaluation of the impact of PE screening, risk status and trial participation on 
women’s experience of pregnancy (data for the current study constitute a sub-section of the 
data collected for this larger project). In this way, we clearly positioned ourselves ‘outside’ of 
the medical research team involved with the recruitment into the trial, in order to facilitate 
engagement and disclosure of personal views. The reply form allowed women to give details 
of how and when they would like to be contacted; they were given the choice of the setting 
for the interview, either at their home or at the hospital. If neither was accepted, a telephone 
interview was offered. Two reminder letters were mailed to those who did not respond. Of 
those who consented, in each group, consecutive women were contacted until the target 
number of interviews was reached. Taking into consideration previous published research5-10, 
12, it was estimated that an interview with 10-12 women in each group would be needed to 
reach data saturation.  
The interview was conducted by the second author (ZD, a PhD student, female, with 
previous training and experience in conducting interviews). The interviews were conducted 
face-to-face, at the woman’s home (participants: n = 6; decliners: n = 2) or the hospital 
(participants: n = 7; decliners: n = 6), unless the woman explicitly requested a telephone 
interview (participants: n = 1; decliners = 5). Where the interviews took place face-to-face, 
the researcher obtained written informed consent; verbal informed consent was obtained 
during telephone interviews. All participants were aware that they had the right to decline 
answering questions if they were uncomfortable and terminate the interview without giving 
reasons and without subsequent influence on their antenatal care. The interviews lasted on 
average 30 minutes; they were audio-recorded. The local National Health Service research 
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Data analysis 
Data for the current study constitute a sub-section of the interview data collected to 
evaluate the impact of PE screening and trial participation on pregnant women. The interview 
transcripts were analysed using template analysis, a method for thematic analysis and 
organisation of data20, previously utilised in healthcare research21,22 . Template analysis was 
chosen because it allows for development of a-priori themes, i.e. themes that are significant 
to the research question, to be developed before data analysis begins.  
The research team consisting of two experienced academic psychologists (AN and JP) 
and a PhD student (ZD) developed an initial template, that drew on previous literature5-10, 12 
and pilot data derived from five participants and three decliners of the ASPRE trial to define 
our codes. Interview data were then mapped onto the initial template during the series of 
weekly meetings. Working collaboratively, we discussed and agreed to discard a priori 
themes and codes if they did not prove to be useful in capturing the key meanings present in 
the data which led to the modifications of the template; where material emerged which did 
not appear adequately covered by an existing code, the template was further modified.  
Previously coded transcripts were then re-coded to the modified template in an iterative 
process. The research team agreed that after about 8 interviews in each participant group, the 
template appeared stable and ZD proceeded to work through the remaining interview 
transcripts individually (the final coding template is available from the corresponding author 
on request).  
Main themes and subthemes, where relevant, are illustrated by the verbatim extracts 
from interviews with both participants and decliners of the ASPRE trial. Whilst main themes 
represent principal findings regarding reasons for women’s participation or non-participation 
in the ASPRE trial, the subthemes (where identified) offer additional discrimination; although 
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all encompassed by the main theme, the subthemes are distinct from each other that is they 
are internally homogenous and externally heterogenous23.  
Results 
Of the 255 ASPRE trial participants approached, 178 (69.8%) did not respond; 63 
(24.7%) responded but declined and 14 (5.5%) agreed to take part in the study. Of the 211 
women ASPRE trial decliners contacted, 183 (86.7%) did not respond, 15 (7.1%) responded 
and declined and 13 (6.2%) agreed to take part in the current study. Amongst those who 
responded but declined participation in the interview study, the most commonly cited reason 
for declining participation was lack of time. We could not identify any systematic differences 
between women who agreed to take part in the study and those who declined. Characteristics 
of the women, both participants and decliners of the ASPRE trial who constituted our study 
sample, are presented in Table 2.  
The context of decision-making: Knowledge and understanding of the ASPRE trial aims 
and procedures 
Two themes, one indicating good understanding and the other indicating absence of clear 
understanding of the ASPRE trial aims and procedural requirements were identified. The 
majority of women (24/27), at an average of 10 weeks since the entry into the trial, were able 
to recall and report at least some of the key details regarding the aims, procedure and 
requirements of the trial.  
“Taking the tablets, they explained everything, the tablets some would be aspirin some 
would be like dummy, they wouldn’t know, we wouldn’t know and to take them every day 
and they gave me the diary and explained if I have any symptoms or anything just to write 
it down.” (Participant 1).  
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In contrast, a limited understanding of the trial’s aims and procedures were shown by three 
women (one participant and two decliners) who could not recall accurately the key aspects of 
the trial.  
 “They said to me that I would need to go in each week for an ECG I think it was and then 
I would just need to take these tablets and then they would see if they would work on like me 
and the other people that were taking part.” (Decliner 11). 
Factors influencing participation  
Five main themes were identified as reasons for participation in the ASPRE trial: 
positive attitudes towards the trial drug aspirin, personal benefit from trial participation, 
altruism, satisfaction with the information received and views of significant others and 
trusted professionals. Some women expressed more than one theme as their reasons for 
participation in the trial. For the theme positive attitudes towards aspirin, two sub-themes 
were established: little risk posed by participating in the trial and preference for taking the 
active tablet.  
Theme 1: Positive attitudes towards aspirin 
Positive attitudes towards aspirin were identified as the key reason for the women’s 
acceptance of trial participation; these were endorsed by the majority of participants (n = 13).  
There was a sense of reassurance that aspirin was being used in the trial, because it was a 
medicine they were familiar with and they were aware of its use for various conditions. 
“I think if it was something other than aspirin…it would’ve been a harder decision but 
because it’s aspirin or nothing it didn’t really…just see it as safe, a lot of people take aspirin 
every day for various different things.” (Participant 14).  
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In their explanations of their decisions to take part in the trial, the women highlighted their 
familiarity with aspirin and simultaneously acknowledged that the alternative was ‘nothing’ 
(ie. placebo) which meant that the trial posed little risk. This is captured by the subtheme:  
Little risk posed by participating in the trial. This sub-theme refers to the women’s 
perception (n = 8) that the trial procedure was appraised as low in risk as it involved either 
taking aspirin (ie a safe drug) or nothing (that is a placebo), which facilitated their 
participation: 
 “I knew its aspirin or placebo, if it would have been a weird drug that I hadn’t known about 
that it would be completely different, because I knew its either aspirin or not than I thought 
it’s fine” (Participant 2) 
Due to these reasons, the decision to take part in the trial was not too difficult for most 
participants. Some women expressed that the reassurance provided by the doctor about the 
safety of aspirin had informed their view that indeed the trial posed little risk to themselves 
and the baby, and taking part was thus preferable to not taking part, given their high-risk 
status.  
“I suppose because if I wasn’t part of the trial I wouldn’t be taking anything anyway. 
It’s not really, I am kind of, I am not losing out” (Participant 8) 
Preference for taking the active tablet (i.e. aspirin). This sub-theme refers to the expressed 
desire of three women who stated that they would have liked to know that they were in the 
active arm of the trial and therefore taking the aspirin tablet rather than a placebo. These 
women’s answers revealed that knowing that they were screened as high-risk of preterm-PE 
created a sense of discomfort and a desire to minimise this risk through taking aspirin.  
 “I would have liked the confirmation that what I am taking is aspirin…if I’ve got a risk I 
want to try the thing that is going to lower that risk.” (Participant 3). 
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However, at the same time, the women recognised the experimental nature of the project and 
the need for randomisation and were happy to comply with the trial requirements.  
Theme 2: Personal benefit from trial participation 
This theme reflects women’s beliefs that by participating in the trial they would personally 
benefit by obtaining superior antenatal care i.e. having additional scans and monitoring; this 
was expressed by 11 out of 14 women. In view of their high-risk status, this additional care 
was seen as a source of comfort and reassurance, preferential to not participating in the trial:  
“I felt more like I was going to get more help. I was going to get more care. For me, that 
was really nice…this time I’ve had extra scans and I have been monitored and my blood 
pressure has been checked more. I think the care has been nice for me.” (Participant 4).  
Theme 3: Altruism 
This theme refers to the altruistic attitudes expressed by 12 participants of the trial. As 
illustrated by the quote below, the majority of women who agreed to participate in the 
ASPRE trial believed that in doing so they would contribute to the medical knowledge 
regarding PE treatment.  
“…probably just to assist with the research to be honest. I know it’s really difficult to recruit 
and I am quite happy to kind of be part of the trial that might make it better in the future, 
which sounds quite altruistic” (Participant 5). 
Theme 4: Satisfaction with the information received 
Satisfaction with the information received by the medical team had a positive impact on 
women’s decision to participate in the ASPRE trial. Eight participants reported feeling 
reassured by the provided information, the way medical professionals answered their 
questions and by the provision of contact details in case of any problems, which facilitated 
their participation in the trial, as illustrated by the quote below: 
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“They were really good to me. Really good. They have been listening to my heart and 
checking how things are going….they gave me enough information to make me want to do 
the trial. It’s helped”. (Participant 4) 
Theme 5: Views of significant others and trusted professionals 
All but one woman reported discussing the trial with their significant others, be it their 
partner, other family members, or professionals they trusted (e.g. midwife): 
“My husband and I had a bit of a discussion what we would lose if we did or didn’t do it, 
so kind of together we decided there was nothing to lose by going through” (Participant 
10) 
The input from others was seen as important, but most women expressed the view that the 
decision was solely theirs or one jointly made with their partner. Some significant others 
were supportive of them taking aspirin or happy to go with whatever decision the woman felt 
comfortable with. One woman reported that her partner did not wish for her to take part but 
she decided to participate regardless of his view.  
Factors influencing non-participation  
Four themes, amongst reasons cited by the decliners of the ASPRE trial were 
identified: negative attitudes towards medications, placebo arm, insufficient information 
about the trial and views of significant others and trusted professionals. Some women 
endorsed more than one of these themes as their reasons for declining participation.  
Theme 1: Negative attitudes towards medications intake in pregnancy  
The most commonly given reason for declining participation, which was discussed by twelve 
women, was negative attitudes towards taking medication during pregnancy. The women’s 
responses highlighted a general unease regarding intake of any medication whilst pregnant:  
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“I wouldn’t have been interested, because I don’t want to take anything, any sort of 
medication. Me personally, it’s just how I am… I didn’t want to be in that position where I 
have to take medication, because I don’t have to, basically” (Decliner 8). 
Although the women acknowledged their high-risk status for preterm-PE, this information 
did not motivate them to take action. The representation of this threat was weighed against 
the ’intrusiveness’ of the preventative trial intervention which was then rejected.  
“..the idea of taking a drug every single day when you are pregnant, even though it’s  known 
to be safe …I would have more kind of acceptable intervention...would be more regular 
blood pressure monitoring or more regular urine samples or something like that, rather 
than taking a drug every day, just because I think you have it so drummed into you that you 
have to be careful what you put in your mouth when you are pregnant. The thought of taking 
a drug every day seems like quite a major thing to do and also quite a medical thing to do” 
(Decliner 1). 
Some women further explained the particular reasons as to why they had a negative attitude 
towards the trial medication including concerns about the safety of aspirin specifically and/or 
their medical history and these are explored in the sub-themes below: 
Concerns about the safety of taking aspirin. This sub-theme refers to the concerns 
about the side effects of aspirin intake, which were expressed by five women. Although the 
women had been informed that adverse effects of aspirin were unlikely and that aspirin was 
not harmful, they stated that they simply did not wish to take any risk. 
“My question was is aspirin dangerous for your unborn child. They were like no, no, 100% 
no danger. I was a bit surprised about that, because I am sure in the literature I read…you 
weren’t supposed to take it, weren’t supposed to take anything other than paracetamol….I 
kind of decided, I’d minimised what I had been taking in terms of drugs and paracetamol 
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and stuff. I wasn’t going to likely start taking aspirin in case there were any side effects.” 
(Decliner 2). 
Medical complications, past and present. Past or existing medical complications and 
conditions also influenced three women who declined participation in the trial. These women 
expressed that adding aspirin to their regime of medications for (pre) existing conditions was 
seen as undesirable, as illustrated below:  
“I’ve got sickle cell disease, there’s other medications I take and I didn’t want to be taking 
so much even though he said that the test you will, you might be on a placebo, you might be 
on a low dose aspirin, I just thought I’m already taking a lot I didn’t really want to add 
another one.” (Decliner 13) 
Theme 2: Placebo arm 
The focus of this theme which we termed ‘the placebo arm’ is on the feelings of discomfort 
and uncertainty that six of the decliners expressed regarding the allocation to the placebo arm 
of the trial or with not knowing in which arm of the trial they would be placed. These two 
sets of concerns are reflected in the two subthemes below wanting a guarantee of taking 
aspirin and “you don’t know what you are taking”: 
Wanting a guarantee of taking aspirin. Four decliners specifically stated that if aspirin 
were effective in reducing the likelihood of developing preterm-PE, they would want the 
guarantee of taking it, rather than the possibility of taking the placebo.  
“If they had just have said to me that it was just aspirin I probably would have done it. No, 
it was the fact that well possibly I could be taking nothing for how many months and what 
good is that going to do for me” (Decliner 12). 
Two women were speaking hypothetically, whilst two others declined participation and took 
aspirin outside of the trial. For the latter two women, the decision to take aspirin was made 
because of the pressure by family members.  
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 “You don’t know what you are taking”. Two women expressed that not knowing 
whether they were taking, aspirin or placebo, would have been confusing to explain to other 
medical professionals should the need for that arise: 
“I know I could have gotten the placebo but em, and I think that as well because also 
not knowing, cos when you’re going for your appointment with your midwife or 
anything had happen and I’d gone in the hospital and they say are you taking any 
medication, to say well I could be but I don’t know, that again is also quite difficult” 
(Decliner 5). 
Theme 3: Insufficient information about the trial  
Three women stated that lack of sufficient information about the trial was a minor 
contributing factor for their non-participation: 
“She couldn’t answer all of my questions, she probably wasn’t expecting me to ask those 
kind of questions, and I think it would have been quite nice if she could have pointed me to 
something. I could have read more to give more details” (Decliner 5) 
Theme 4: Views of significant others and trusted professionals 
Similarly to the participants of the trial, nine women decliners reported discussing their 
decision with family members and one woman reported talking to her midwife. Six women 
reported that their family members’ negative attitudes towards medication intake in 
pregnancy reaffirmed their decision to decline participation:   
 “I brought my mom cos I always bring someone to my hospital appointment…and they told 
me about the research and even I said no ..she said yeah you made the right choice even I 
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Discussion 
Women at high-risk of developing preterm-PE were invited to take part in a RCT, the ASPRE 
trial, to examine whether aspirin can prevent the occurrence of this condition. Our study 
findings demonstrated that the majority of both participants and decliners, at approximately 
three months since being invited into the ASPRE trial, had a good level of understanding and 
recall of the trial’s aims and procedural requirements.  
Self-regulation of health and illness theory 15,16 suggests that the motivational impact 
of high-risk information depends on the representation of that risk which will influence 
individual’s cognitive and behavioural attempts to minimise health threat and associated 
emotional reactions. Recently, Harris and colleagues24 used the self-regulation theory to 
understand the psychological impact of high-risk PE status on pregnant women. In line with 
other studies which suggest that an individual’s perception of risk may not always align with 
professionals’ views25,26, Harris and colleagues suggested that women found to be at high-
risk for PE did not perceive themselves to be at risk for the condition. In managing the threat 
posed by the positive screening result some women named by the researchers ‘danger 
managers’ focused on the consequences of this result on themselves and chose behavioural 
pathways to manage threat via information seeking, positive behavioural changes and 
cognitive reappraisals, as their preferred coping strategies. In contrast, women named ‘fear 
managers’ focussed on the fetal consequences of PE and they chose avoidance and threat 
minimisation to cope with the positive PE screening result.  
All women in our study were aware of their high-risk status for preterm-PE which 
they recognised to be the reason to have been invited to take part in the ASPRE trial. For 
participants of the ASPRE trial, their high-risk status represented a threat which seemed to 
have motivated them towards engagement in action to prevent PE; thus taking part in the trial 
could be seen as a behavioural pathway to manage threat posed by the high risk test result, 
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similar to the ‘danger managers’ active approach to coping with their high-risk status. The 
familiarity and the perceived safety of the trial drug (aspirin) and the procedure, together with 
the reassurance provided by the doctors that taking aspirin would cause little or no side 
effects or risk to themselves or the baby, were important in arriving at the view that the trial 
posed little threat.  Few participants of the trial expressed that knowing that they were high-
risk meant that they would have preferred taking aspirin rather than the placebo; however, 
they were willing to accept the clinical equipoise inherent in the trial and the need for 
randomisation. A preference for the active drug in medicated clinical trials is often reported5. 
Participants also felt motivated to take part in the trial as they would be in receipt of 
additional scans and monitoring during pregnancy, which was reassuring given their high-risk 
status. Apart from personal benefit they also endorsed wishing to contribute to the medical 
knowledge; altruistic beliefs, but only when self-interests are also endorsed, as appeared to be 
the case in our sample, have been referred to as ‘weak altruism’27, and have been identified 
by other studies6,8.   
Contrary to the participants, the majority of decliners expressed negative attitudes 
towards taking any medications in pregnancy. Similarly to the ‘fear managers’, these women 
chose to avoid or decline participation in the trial based on their rejection of the intake of 
aspirin which they perceived as an excessive request. The women seem to wish to minimise 
any potential harm or danger that could be caused by medication intake; for most, this was 
not specifically about aspirin, but more about a desire to minimise any medication intake 
whilst pregnant. During their decision-making, many decliners seemed to struggle to 
accommodate apparently discordant messages from the medical professionals: the commonly 
advocated message of avoiding medicines in pregnancy and the request of taking aspirin 
through the ASPRE trial participation. Participation in the trial was declined by some women 
on the grounds that aspirin was not a proven method of PE risk reduction, or that it would be 
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difficult to explain trial participation to other medical professionals,  and hence they did not 
wish to partake in the trial, again minimising any potential for harm. In contrast, for a few 
women decliners of the trial, their high-risk status activated beliefs concerning the necessity 
of action on their part and they declined participation as they wanted the certainty of taking 
aspirin rather than allowing the possibility of being in the placebo arm of the trial. They 
subsequently took aspirin outside of the trial. For this subset of women decliners, the threat 
caused by their high-risk status seem to be so significant that it motivated them to engage in 
what they saw may be a more certain preventative action against developing preterm PE 
compared to taking part in the trial where they could be in the placebo arm. This, in a few 
instances, occurred because of the pressure of significant others. 
In line with other studies7,9,10, views of important and trusted individuals, and 
women’s partners in particular, played a role during women’s decision-making regarding 
participation in the trial. Social support can relieve anxiety in pregnant women28 and increase 
the uptake of behaviour change29. In our study, the views of significant others seemed to have 
reinforced women’s decision regarding participation. Only in a few cases, the women stated 
feeling pressured to take the aspirin (outside of the trial) or they decided to take part in the 
trial against the wishes of their partner.  
Some limitations to our study must be noted. First, the study findings reported here 
are based on in-depth exploration of the reasons regarding participation in the ASPRE trial in 
a small number of high-risk women in two London hospitals, who were mostly Caucasian, 
well-educated, and living with their partners. These views might not be generalisable to all 
women, across the six countries, who accepted or declined participation in the ASPRE trial. 
Secondly, the response rate to our qualitative study was low, although it was in line with 
another similar study with high-risk decliners12. Thirdly, we suggested that psychological 
theories and, in particular the self-regulation theory, can be a useful heuristic to understand 
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women’s motivation to take part in the medicated clinical trials. Central to women’s coping 
responses are their representations of threat posed by their risk-status. Whilst we did not 
specifically examine women’s representations of their PE risk-status and related them to their 
uptake of trial participation, we proposed that this may be a way of understanding why 
women, presented with the same risk status information, chose different paths to deal with the 
uncertainty and threat posed by it. We suggest that future research in the area should examine 
the relevance of the self-regulation theory more specifically in the context of the uptake of 
participation in clinical trials in women at high-risk. Notwithstanding the above limitations, 
our study offers insights from both participants and decliners, the latter group often neglected 
in research, as to what motivated pregnant women to partake or not in a medicated trial for 
the prevention of preterm-PE.  
There are a number of implications of our findings. Medicated clinical trials in 
pregnancy are likely to represent a significant challenge for the recruiters. The ASPRE trial 
succeeded in achieving high recruitment rates but this may not be the case with less familiar 
and known medications. As our findings have shown, information regarding safety are of 
paramount importance to the women invited to participate in a medicated clinical trial. In-
person recruitment, that would allow women and their partners an opportunity to address 
concerns about research safety and procedure, and deal with fear and anxiety concerning 
medication intake in pregnancy, that are likely to mediate willingness to participate, would be 
of crucial importance. Such in-person recruitment would also allow delivery of information 
regarding the importance of participation for altruistic reasons that many women identified as 
important to them. Apart from recruiters, our study findings also offer useful insights to the 
clinicians providing counselling to women identified at high-risk of preterm-PE regarding the 
potential barriers to prophylactic treatment. Including women’s partners in counselling 
regarding medicated treatment in pregnancy, as our findings suggest, would be important so 
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that the pregnant woman and her partner’s concerns are jointly considered. In this way the 
health professionals will be able to assist the pregnant woman to make informed choices that 
would enhance her health and pregnancy outcomes.  
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Table 1. Topic guide 
 
In the interviews we explored: 
 
a. Women’s knowledge and understanding of the trial’s aims and the procedure  
Example question: Can you remember what you were told about what was the aim of the 
trial? 
 
b. Women’s decision making concerning participation in the trial: how did they make a 
decision, whether they had enough information to make a decision, their concerns about 
taking part, and whether they had discussed their decision with anyone? 
Example question: Did you discuss your decision with anyone, for example your partner or  
other family members? 
 
c. Factors influencing their decision to take part or to decline participation 
Example question: What were your main reasons for taking part/declining to take part in 
the trial? 




Table 2. Sample characteristics 
 Participants (14) Decliners (13) 
 N % N % 
Ethnicity   
Caucasian 9 64 7 54 
Black 4 29 5 38 
South Asian 1 7 1 8 
Education     
Primary school 0 0 1 8 
A levels or equivalent 1 7 3 23 
University degree 7 50 5 38 
             Postgraduate degree 6 43 4 31 
Marital Status     
            Living with partner 12 86 12 92 
            In a relationship but not living together 1 7 1 8 
            Single 1 7 0 0 
Pregnancy history     
            Previous pregnancy 2 15 4 31 
            First pregnancy 12 86 9 69 
Medical complications     
            None 12 86 12 92 
            Asthma 2 14 0 0 
            Polycystic ovaries syndrome 0 0 1 8 
 
 
 
